



A Satellite Symposium
at EULAR 2016
London, UK

Organised by the BIOSIMILAR MEDICINES GROUP



Save the Date

Biosimilar Medicines for Rheumatologists: Understanding the Science of Extrapolation

Friday 10th June, 08:15–09:45

Capital Suite 09, ExCel London



The Biosimilar Medicines Group, a sector group of Medicines for Europe, acknowledges the financial support of the following member companies in funding this symposium:





A Satellite Symposium
at EULAR 2016
London, UK

Dear Colleague

You are warmly invited to attend **Biosimilar Medicines for Rheumatologists: Understanding the Science of Extrapolation**

an educational symposium organised by the **Biosimilar Medicines Group**, a sector group of Medicines for Europe.

Biosimilars have been available in Europe for 10 years, for use in areas such as endocrinology and supportive cancer care. Recently, the European Commission has approved biosimilar products bearing infliximab and etanercept following the European Medicines Agency's positive scientific opinion; these medicinal products are therefore now a reality in rheumatology. A clear understanding of the scientific principles of the biosimilarity concept is important for physicians to make informed treatment choices for their patients. Extrapolation of indications is a key element of the biosimilarity concept, while interchangeability is another 'hot topic' in this area. We have therefore gathered together an impressive faculty to provide you with the latest thinking, from a regulatory, scientific and clinical perspective, on these interesting and important topics.

I hope you can join us in London for what is sure to be a very popular and highly informative symposium.

Fernando de Mora
Symposium Chair

Programme

Welcome and introduction	5 mins
Professor Fernando de Mora <i>Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Spain</i>	
Biosimilars: the science of extrapolation and interchangeability	30 mins
Elena Wolff-Holz, MD <i>Senior Medical Assessor, Paul Ehrlich Institute, Germany Member of the European Medicines Agency's Biosimilar Medicinal Products Working Party (BMWP) and Oncology Working Group (OWP)</i>	
The EULAR position in the making	20 mins
Professor Ferdinand Breedveld <i>Head of Department of Internal Medicine and Rheumatology, Leiden University Medical Centre, The Netherlands Past-President of EULAR</i>	
Panel discussion, Q&A	30 mins
Above faculty members plus Professor Tore Kvien <i>Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway Editor of Annals of Rheumatic Diseases</i>	
Summary and close	5 mins
Professor Fernando de Mora	